Comparative Pharmacology
Head-to-head clinical analysis: ILLUCCIX versus POSLUMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILLUCCIX versus POSLUMA.
ILLUCCIX vs POSLUMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle, leading to bronchodilation.
PSMA-targeted radiotherapeutic agent; emits beta radiation causing DNA damage and cell death in PSMA-expressing cells.
10 mg orally once daily, with or without food.
1.85 MBq (0.05 mCi)/kg intravenously as a single injection, followed by PET imaging approximately 60 minutes post-injection.
None Documented
None Documented
Terminal elimination half-life is 4–6 hours in patients with normal hepatic function; may be prolonged in hepatic impairment.
Terminal elimination half-life: approximately 25–30 minutes for [68Ga]Ga-PSMA-11; rapid clearance from blood pool due to renal and hepatobiliary elimination.
Primarily hepatic metabolism with renal elimination of metabolites: ~30% unchanged in urine, <5% in feces.
Renal: 0% (not significantly eliminated via kidneys); Biliary/Fecal: predominantly eliminated via hepatobiliary system with fecal excretion of intact complex and metabolites, though precise % not established for human.
Category C
Category C
Radiopharmaceutical Diagnostic Agent
Radiopharmaceutical Diagnostic Agent